Vericel

OverviewSuggest Edit

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The Company markets two cell therapy products in the United States. Carticel (autologous cultured chondrocytes) is an autologous chondrocyte implant intended to treat cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 2 additional cell products. MACI is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM).

TypePublic
Founded1989
HQCambridge, MA, USMap
Websitevcel.com
Employee Ratings3.1More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)241(+12%)
Revenue (FY, 2019)$117.9 M(+30%)
Share Price (Feb 2021)$49.7 (+6%)
Cybersecurity ratingCMore

Key People/Management at Vericel

Dominick Colangelo

Dominick Colangelo

President & CEO
Mike Halpin

Mike Halpin

Chief Operating Officer
Joe Mara

Joe Mara

Chief Financial Officer
Jonathan Hopper

Jonathan Hopper

Chief Medical Officer
Roland Deangelis

Roland Deangelis

Senior Vice President, Commercial Operations
Heidi Hassen

Heidi Hassen

Vice President, Human Resources
Show more

Vericel Office Locations

Vericel has offices in Cambridge and Ann Arbor
Cambridge, MA, US (HQ)
64 Sidney St
Show all (2)

Vericel Financials and Metrics

Vericel Revenue

Embed Graph
View revenue for all periods
Vericel's revenue was reported to be $117.85 m in FY, 2019
USD

Revenue (Q3, 2020)

32.3m

Gross profit (Q3, 2020)

22.5m

Gross profit margin (Q3, 2020), %

69.7%

Net income (Q3, 2020)

3.6m

EBIT (Q3, 2020)

3.5m

Market capitalization (8-Feb-2021)

2.3b

Closing stock price (8-Feb-2021)

49.7

Cash (30-Sept-2020)

43.5m

EV

2.2b
Vericel's current market capitalization is $2.3 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

18.0k21.0k19.0k28.8m51.2m54.4m63.9m90.9m117.9m

Revenue growth, %

78%6%

Cost of goods sold

4.0k6.0k4.0k17.3m26.5m28.3m30.4m32.2m37.6m

Gross profit

14.0k15.0k15.0k11.5m24.7m26.1m33.6m58.7m80.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

9.0k2.0k8.0k3.0k4.4m9.7m10.8m13.6m11.3m14.1m12.8m10.9m9.4m17.0m14.3m18.0m19.0m22.5m22.0k26.2m30.5m26.7m20.0m32.3m

Cost of goods sold

2.0k2.0k2.0k1.0k5.0m5.5m5.6m6.9m6.8m6.6m7.3m6.9m7.1m7.7m7.2m7.7m9.9m8.7m9.8m

Gross profit

7.0k6.0k2.0k(577.0k)4.1m5.3m6.7m4.5m7.5m5.5m4.1m2.3m9.3m7.1m10.4m16.8m11.4m22.5m

Gross profit Margin, %

78%75%67%(13%)43%49%49%40%54%43%37%24%55%50%57%63%57%70%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.5m13.6m8.1m30.3m14.6m23.0m26.9m18.3m26.9m

Accounts Receivable

9.0k28.0k8.2m10.9m17.1m18.3m23.5m32.2m

Prepaid Expenses

636.0k324.0k417.0k1.0m464.0k1.6m2.8m3.0m

Inventories

1.9m1.4m3.5m3.8m3.6m6.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

18.5m11.9m36.7m28.7m21.1m9.2m4.5m10.8m8.8m7.3m37.6m25.9m20.2m18.7m13.5m9.8m8.9m19.8m14.0m15.5m29.8m95.0m53.3m35.1m14.0m36.9m45.6m55.7m43.5m

Accounts Receivable

9.0k11.0k9.0k9.0k4.3m4.0m9.2m9.0m7.6m9.7m9.0m7.9m12.1m14.7m15.4m13.2m17.5m15.5m18.8m21.1m20.0m24.2m23.7m26.2m

Prepaid Expenses

524.0k622.0k453.0k455.0k364.0k300.0k236.0k545.0k400.0k610.0k1.5m845.0k2.3m514.0k662.0k1.0m741.0k1.0m1.1m1.4m1.4m1.3m2.3m2.7m2.2m3.3m

Inventories

1.9m1.7m2.0m2.1m1.6m1.9m2.4m3.6m4.0m3.2m4.0m3.9m3.7m3.6m4.1m4.8m6.8m7.3m8.4m10.1m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(19.7m)(29.5m)(15.6m)(19.9m)(16.3m)(19.6m)(17.3m)(8.1m)

Depreciation and Amortization

647.0k649.0k489.0k752.0k1.6m1.9m1.6m1.4m1.7m

Inventories

119.0k(86.0k)(2.2m)(657.0k)235.0k(3.3m)

Accounts Payable

63.0k284.0k(571.0k)2.8m1.7m(1.1m)(1.4m)899.0k(1.0m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(14.9m)(16.9m)(9.5m)(16.8m)(22.8m)(5.5m)(10.4m)(12.7m)(6.0m)(10.6m)(17.5m)(4.9m)(7.0m)(11.4m)(3.6m)(6.7m)(13.4m)(9.8m)(12.2m)(17.6m)(7.7m)(12.3m)(13.4m)(2.8m)(13.0m)(9.4m)

Depreciation and Amortization

296.0k464.0k179.0k341.0k487.0k150.0k275.0k387.0k97.0k246.0k496.0k328.0k672.0k1.2m445.0k923.0k1.4m409.0k784.0k1.2m427.0k813.0k1.1m324.0k698.0k1.2m533.0k1.1m1.6m

Inventories

(1.0k)278.0k489.0k(85.0k)(157.0k)(339.0k)(580.0k)(1.1m)(2.3m)(563.0k)173.0k(793.0k)(18.0k)302.0k(148.0k)(505.0k)(1.2m)(3.3m)(466.0k)(1.6m)(3.3m)

Accounts Payable

(436.0k)(452.0k)421.0k821.0k281.0k(232.0k)87.0k(329.0k)(201.0k)4.6m(69.0k)460.0k(412.0k)(899.0k)(2.0m)(2.3m)(2.2m)(300.0k)(404.0k)(1.1m)(229.0k)(1.0m)(1.2m)(1.4m)(2.2m)(1.9m)(59.0k)(1.7m)(52.0k)
show all
USDQ2, 2011

Financial Leverage

-2 x
Show all financial metrics

Vericel Operating Metrics

FY, 2016

Approval Phase Products

3

Phase II Trials Products

1
Show all operating metrics

Vericel Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

Learn more about our premium products
SecurityScorecard logo

Vericel Online and Social Media Presence

Vericel's Trends

Embed Graph

Vericel Company Culture

  • CEO Rating

    A+

    100/100

  • Compensation

    F

    10/100

Learn more on Comparably

Vericel News and Updates

January 25, 2021

Vericel Announces Appointment of Joe Mara as Chief Financial Officer

CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of Joe Mara as Chief Financial Officer of the Company, effective today.
January 11, 2021

Vericel Announces Preliminary Fourth-Quarter and Full-Year 2020 Financial Results and Provides Business Updates

Record Quarterly and Full-Year Total Revenues
January 08, 2021

Vericel to Present at the 23rd Annual Needham Growth Conference on Friday, January 15, 2021

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 23rd Annual Needham Gr…
January 07, 2021

Vericel Announces Expansion of MACI Coverage by UnitedHealthcare to Include Patella and Multiple Cartilage Defects in the Knee

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that UnitedHealthcare has expanded its medical policy for MACI® (autologous cultured chondrocytes on porcine c…
December 18, 2020

Vericel to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021

CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 39th Annual J.P. Morga…
October 22, 2020

Vericel to Report Third-Quarter 2020 Financial Results on November 5, 2020

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2020 financial results and business hig…
Show more

Vericel Blogs

November 05, 2020

Vericel Reports Record Third Quarter Revenues and Net Income

Total Net Revenues of $32.3 Million and Net Income of $3.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) --  Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported
November 02, 2020

Vericel to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations at the following upcoming investor conferences. The Credit Suisse 29 th Annual Healthcare
October 14, 2020

Vericel Announces Preliminary Third Quarter 2020 Total Net Revenues of $32 Million

Double-Digit Revenue, Implant and Biopsy Growth for MACI in the Quarter and Record Monthly Biopsies in September Approximately $4.6 Million of Operating Cash Flow for the Quarter CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
August 25, 2020

MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness

YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant
July 22, 2020

Vericel to Report Second-Quarter 2020 Financial Results on August 5, 2020

CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2020 financial results and business
July 09, 2020

Vericel Announces Preliminary Second Quarter 2020 Financial Results and Provides Business Updates

Vericel Announces Preliminary Second Quarter 2020 Financial Results and Provides Business Updates Content Import Thu, 07/09/2020 - 08:30 Vericel Announces Preliminary Second Quarter 2020 Financial Results and Provides Business Updates July 9, 2020 at 8:30 AM EDT …
Show more

 Vericel Frequently Asked Questions

  • When was Vericel founded?

    Vericel was founded in 1989.

  • Who are Vericel key executives?

    Vericel's key executives are Dominick Colangelo, Mike Halpin and Joe Mara.

  • How many employees does Vericel have?

    Vericel has 241 employees.

  • What is Vericel revenue?

    Latest Vericel annual revenue is $117.9 m.

  • What is Vericel revenue per employee?

    Latest Vericel revenue per employee is $489 k.

  • Who are Vericel competitors?

    Competitors of Vericel include MODAG, Fratagene Therapeutics and Clover Biopharmaceuticals.

  • Where is Vericel headquarters?

    Vericel headquarters is located at 64 Sidney St, Cambridge.

  • Where are Vericel offices?

    Vericel has offices in Cambridge and Ann Arbor.

  • How many offices does Vericel have?

    Vericel has 2 offices.